Eli Lilly (LLY) Non-Current Assets (2009 - 2026)

Eli Lilly has reported Non-Current Assets for 18 years, with the latest figure at $61.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 28.29% year-over-year to $61.7 billion; the trailing twelve-month figure through Mar 2026 stood at $222.5 billion (up 23.65% YoY), and the FY2025 full-year result was $56.8 billion, up 23.65% from the prior year.
• Non-Current Assets for Q1 2026 stood at $61.7 billion, up from $56.8 billion in the prior quarter.
• The five-year high for Non-Current Assets was $61.7 billion in Q1 2026, with the low at $29.8 billion in Q3 2022.
• Historically, Non-Current Assets has averaged $41.3 billion across 5 years, with a median of $38.8 billion in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets decreased 1.85% — and 2026, when it grew 28.29%.
• Eli Lilly's Non-Current Assets stood at $31.5 billion in 2022, then gained by 21.69% to $38.3 billion in 2023, then advanced by 20.1% to $46.0 billion in 2024, then rose by 23.65% to $56.8 billion in 2025, then grew by 8.61% to $61.7 billion in 2026.
• The last three Non-Current Assets figures came in at $61.7 billion (Q1 2026), $56.8 billion (Q4 2025), and $52.9 billion (Q3 2025), per Business Quant data.